LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

1.43 11.72

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.3

Max

1.46

Chiffres clés

By Trading Economics

Revenu

206K

-60M

BPA

-0.28

Marge bénéficiaire

272,450

Employés

226

EBITDA

-302K

-56M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+500.78% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

22M

278M

Ouverture précédente

-10.29

Clôture précédente

1.43

Sentiment de l'Actualité

By Acuity

60%

40%

334 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 juin 2025, 14:31 UTC

Résultats

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 juin 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 juin 2025, 20:33 UTC

Résultats

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 juin 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 juin 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 juin 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 juin 2025, 16:35 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 16:34 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 juin 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 juin 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 juin 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 juin 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 juin 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 juin 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 juin 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 juin 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 juin 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 juin 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 juin 2025, 14:12 UTC

Résultats

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 juin 2025, 14:09 UTC

Résultats

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

500.78% hausse

Prévisions sur 12 Mois

Moyen 7.75 USD  500.78%

Haut 14 USD

Bas 2.5 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

10

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

1.18 / 1.69Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

334 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.